Einstein (Sao Paulo, Brazil) · 2026
Assessment of medullary response through cellular immaturity parameters in patients undergoing hematopoietic stem cell transplantation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fogo Bruno Gabriel Nardini, Esteves Iracema, Hamerschlak Nelson, Bub Carolina Bonet, Penteado Rosana Moreira Cosentino, Vilarinho Andréa Aparecida Rocco, Guerra João Carlos de Campos
Аннотация
OBJECTIVE: This study aimed to evaluate relative immature platelet fraction (IPF%), absolute immature platelet fraction (A-IPF), and relative immature reticulocyte fraction (IRF%) as biomarkers of bone marrow recovery after hematopoietic stem cell transplantation and to assess their potential role in reducing prophylactic platelet transfusions.
METHODS: Sixty hematopoietic stem cell transplantation recipients (mean age, 50 years) were analyzed, and sex-specific reference ranges for IPF%, A-IPF, and IRF% were established. The predictive performance for platelet engraftment and transfusion requirements was assessed using receiver operating characteristic curve analysis, logistic regression, Fine-Gray competing risks models, Cox regression, and negative binomial modeling.
RESULTS: Only A-IPF differed significantly between groups. An A-IPF threshold greater than 1,450 predicted platelet engraftments within two days with a sensitivity of 82.1% and a specificity of 80.0%. Logistic regression demonstrated a 2.3-fold increase in the likelihood of platelet engraftment for every 1,000-unit increase in A-IPF, and Fine-Gray analysis confirmed a higher cumulative incidence of engraftment in the intermediate and high A-IPF strata (subdistribution hazard ratios, 2.71 and 3.58; p<0.001). All patients required platelet transfusions (149 events). Cox regression identified A-IPF as an independent risk factor for transfusion (hazard ratio, 1.0001; p=0.027), whereas platelet count showed a protective effect (hazard ratio, 0.959; p<0.001). Negative binomial modeling demonstrated that higher weekly mean A-IPF was associated with fewer subsequent transfusions.
CONCLUSION: A-IPF is a robust biomarker for early platelet engraftment and a clinically relevant predictor of platelet transfusion requirements in patients undergoing hematopoietic stem cell transplantation.
METHODS: Sixty hematopoietic stem cell transplantation recipients (mean age, 50 years) were analyzed, and sex-specific reference ranges for IPF%, A-IPF, and IRF% were established. The predictive performance for platelet engraftment and transfusion requirements was assessed using receiver operating characteristic curve analysis, logistic regression, Fine-Gray competing risks models, Cox regression, and negative binomial modeling.
RESULTS: Only A-IPF differed significantly between groups. An A-IPF threshold greater than 1,450 predicted platelet engraftments within two days with a sensitivity of 82.1% and a specificity of 80.0%. Logistic regression demonstrated a 2.3-fold increase in the likelihood of platelet engraftment for every 1,000-unit increase in A-IPF, and Fine-Gray analysis confirmed a higher cumulative incidence of engraftment in the intermediate and high A-IPF strata (subdistribution hazard ratios, 2.71 and 3.58; p<0.001). All patients required platelet transfusions (149 events). Cox regression identified A-IPF as an independent risk factor for transfusion (hazard ratio, 1.0001; p=0.027), whereas platelet count showed a protective effect (hazard ratio, 0.959; p<0.001). Negative binomial modeling demonstrated that higher weekly mean A-IPF was associated with fewer subsequent transfusions.
CONCLUSION: A-IPF is a robust biomarker for early platelet engraftment and a clinically relevant predictor of platelet transfusion requirements in patients undergoing hematopoietic stem cell transplantation.